Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L. Lampson, Jennifer R. Brown, Siddha Kasar et al.|Blood|2016Cited by 289
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|The Lancet Oncology|2021Cited by 102
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L. Lampson, Matthew S. Davids|Current Hematologic Malignancy Reports|2017Cited by 55
Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κBBenjamin L. Lampson, William G. Kaelin|Cell|2024Cited by 45
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Heather A. Walker et al.|Journal of Clinical Oncology|2024Cited by 40